Table 1 Patient cohort
From: Spatial tumor immune microenvironment phenotypes in ovarian cancer
|  | Total cohort n = 64 | Tumor data n = 50 | Tumor+Immune data n = 27 |
|---|---|---|---|
Age at diagnosis (years) | |||
Median | 59 | 57 | 54 |
Min | 21 | 25 | 28 |
Max | 87 | 87 | 87 |
Malignant/Borderline/Benign | |||
Malignant | 53 | 43 | 26 |
Borderline | 7 | 6 | 0 |
Benign | 4 | 1 | 1 |
Stage | |||
I | 32 | 24 | 14 |
II | 5 | 4 | 2 |
III | 20 | 19 | 8 |
IV | 3 | 2 | 2 |
NA (benign) | 4 | 1 | 1 |
Histology | |||
HGSC | 25 | 23 | 14 |
LGSC | 5 | 5 | 3 |
Endometrioid | 12 | 6 | 4 |
Mucinous | 6 | 5 | 2 |
Clear cell | 5 | 4 | 3 |
Benign/borderline | 11 | 7 | 1 |
Type | |||
Type 1 | 28 | 20 | 12 |
Type 2 | 25 | 23 | 14 |
NA (benign/borderline) | 11 | 7 | 1 |
Progression-free survival (yrs) | |||
Average | 8.4 | 8.0 | 7.6 |
Min | 0.5 | 0.5 | 0.6 |
Max | 15.8 | 15.8 | 15.7 |
Response to therapy | |||
Complete response | 42 | 34 | 19 |
Partial response | 4 | 4 | 2 |
Stable disease | 1 | 1 | 1 |
Progressive disease | 1 | 1 | 1 |
Not reported | 16 | 10 | 4 |
Progression during follow-up | |||
Yes | 24 | 22 | 14 |
No | 31 | 23 | 10 |
Not reported | 9 | 5 | 3 |
Cause of death | |||
Ovarian cancer | 16 | 15 | 9 |
Ovarian cancer treatment | 1 | 1 | 0 |
Other | 2 | 1 | 1 |
NA (alive at end of follow-up) | 27 | 20 | 8 |
Not reported | 18 | 13 | 9 |
